|
|
Article: Enzon, Micromet Collaborate On Single-Chain Antibody Program.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
Enzon Inc. and Micromet AG signed a multiyear deal to combine their patents and knowledge to develop single-chain antibody therapeutics.
While Enzon, of Piscataway, N.J., and Micromet, of Munich, Germany, intend to equally share the costs of research and development, Enzon agreed to make an $8 million investment in Micromet, a privately held company.
In exchange, Enzon is expecting that Micromet will help it enter the market more quickly with new products, Kenneth Zuerblis, EnzonEs vice president of finance and chief financial officer, told BioWorld Today.
Even though Enzon acquired single-chain antibody (SCA) ...
Related newspaper, magazine, and journal articles:
|
|
Article: Enzon, Pharmagene Developing PEGylated Cystic Fibrosis ...
BIOWORLD Today;
November 3, 2009 ;
700+ words
... ... un-PEGylated product. But Enzon has rights, and a share in ... commercialization purposes and Enzon would receive certain co ... royalty rates," Zuerblis told BioWorld Today. Peg-Intron is the company ... based Schering-Plough Corp. Enzon receives between a 7 percent ...
|
|